Cancer biology in diabetes update: Focusing on antidiabetic drugs.
Emi KawakitaKeizo KanasakiPublished in: Journal of diabetes investigation (2024)
The association of type 2 diabetes with certain cancer risk has been of great interest for years. However, the effect of diabetic medications on cancer development is not fully understood. Prospective clinical trials have not elucidated the long-term influence of hypoglycemic drugs on cancer incidence and the safety for cancer-bearing patients with diabetes, whereas numerous preclinical studies have shown that antidiabetic drugs could have an impact on carcinogenesis processes beyond the glycemic control effect. Because there is no evidence of the safety profile of antidiabetic agents on cancer biology, careful consideration would be required when prescribing any medicines to patients with diabetes and existing tumor. In this review, we discuss the potential influence of each diabetes therapy in cancer 'initiation', 'promotion' and 'progression'.
Keyphrases
- type diabetes
- papillary thyroid
- glycemic control
- squamous cell
- clinical trial
- cardiovascular disease
- primary care
- emergency department
- randomized controlled trial
- lymph node metastasis
- metabolic syndrome
- stem cells
- risk assessment
- blood glucose
- young adults
- childhood cancer
- cell therapy
- climate change
- drug induced
- smoking cessation
- human health
- open label